MONTPELLIER, France–(BUSINESS WIRE)–Medincell (Euronext: MEDCL) announces that, for operational reasons, the publication of its half-year financial results (April 1st –September 30, 2026) has been rescheduled to Wednesday, December 9, 2026, instead of the originally scheduled date of Tuesday, December 8, 2026. About Medincell Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple ther
